Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01521039 · ClinicalTrials.gov registry record
Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 259
- Enrollment target
NCT01521039: Completed study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT01521039 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 259 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01521039 has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 259 participants
- Enrollment target
Study Summary
Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease (GVHD).
Interventions
- PROCEDURE Blood samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2012-02-20 |
| Est. Completion | 2024-12-30 |
What the finished NCT01521039 record still lists
NCT01521039 is an observational study that tracks outcomes without assigning an intervention. The registered 259 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Blood samples is the first listed.
NCT01521039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01521039 about?
NCT01521039 is a clinical study titled "Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease". Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease (GVHD).
What is the current status of trial NCT01521039?
This trial is currently completed. The enrollment target is 259 participants. The study started on 2012-02-20. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT01521039?
The interventions under investigation include: Blood samples (PROCEDURE).
Who is sponsoring clinical trial NCT01521039?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02361320 · 259 participants · NA
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
- NCT06797258 · 259 participants · NA
FlexHD® Pliable Investigation in Implant-Based Breast Reconstruction
- NCT06990425 · 259 participants · NA
CLOSM Trial: Groin Closure Using Layered Option for Suture Material
- NCT07399977 · 259 participants · NA
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI